Licence extension for Decapeptyl SR

Licence changes apply to Decapeptyl SR 3mg and 11.25mg presentations
Licence changes apply to Decapeptyl SR 3mg and 11.25mg presentations

In addition to use in metastatic prostate cancer and as an alternative to castration in locally advanced prostate cancer, Decapeptyl SR (triptorelin) is now licensed for use as an adjunct to radiotherapy in high-risk localised or locally advanced prostate cancer.

The approved dose of the prolonged-release GnRH analogue is 3mg every 28 days or 11.25mg every 3 months, by intramuscular injection. The six-monthly 22.5mg presentation is not currently licensed for the new indication.

View Decapeptyl SR drug record

Further Information: Ipsen

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in